ZEO ScientifiX Inc

ZEOX.PK has a negative equity position of -$1.423 million and a debt-to-equity ratio of -0.25, indicating a capital structure that is heavily leveraged against equity. The company's liquidity is constrained, with a current ratio of 0.33, suggesting that it may struggle to meet short-term obligations without external financing. The negative free cash flow of -$5.471 million and operating cash flow of -$718,000 further highlight the company's cash flow challenges. Profitability metrics show a mixed picture. The company reported a gross profit of $4.268 million, but this was offset by an operating loss of $5.386 million and a net loss of $5.521 million. The return on equity of 3.88 is positive but misleading due to the negative equity base, while the return on assets of -3.62 indicates that the company is not generating returns from its asset base. ZEOX.PK's revenue is concentrated in its RAAM Products and related services, with no disclosed geographic diversification. The company's business model is centered on clinical-stage development and distribution through healthcare providers, with no material revenue from other segments or geographic regions. The company's growth trajectory is uncertain. With a revenue of $5.199 million, ZEOX.PK has not provided forward-looking guidance, and its operating losses suggest a lack of near-term profitability. The absence of a clear revenue growth path and the need for continued capital raises raise concerns about long-term sustainability. Risk factors include liquidity constraints, with negative net cash after subtracting total debt, and the potential for dilution if the company requires additional capital. The company's dilution risk is currently assessed as low, but the negative equity position and ongoing losses could increase this risk in the future. Recent events include the continued development and distribution of RAAM Products, with the company exploring additional products for topical aesthetic applications. No recent filings or transcripts have been disclosed that provide further insight into the company's strategic direction or financial health.